- Home
- INVE vs GNLX Comparison
INVE vs GNLX Comparison
Compare INVE & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | GNLX |
|---|---|---|
| Founded | 1990 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.1M | 202.4M |
| IPO Year | 1997 | 2023 |
Fundamental Metrics
Financial Performance| Metric | INVE | GNLX |
|---|---|---|
| Price | $3.31 | $2.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.50 | ★ $19.75 |
| AVG Volume (30 Days) | 29.1K | ★ 331.4K |
| Earning Date | 03-04-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,015,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.86 | $1.99 |
| 52 Week High | $4.07 | $8.54 |
Technical Indicators
Market Signals| Indicator | INVE | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.58 | 27.50 |
| Support Level | $3.41 | $2.52 |
| Resistance Level | $3.69 | $2.80 |
| Average True Range (ATR) | 0.19 | 0.33 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 2.88 | 4.25 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.